These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1220 related articles for article (PubMed ID: 30383171)

  • 21. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
    Kraigher-Krainer E; Shah AM; Gupta DK; Santos A; Claggett B; Pieske B; Zile MR; Voors AA; Lefkowitz MP; Packer M; McMurray JJ; Solomon SD;
    J Am Coll Cardiol; 2014 Feb; 63(5):447-56. PubMed ID: 24184245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
    Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Von Willebrand factor improves risk prediction in addition to N-terminal pro-B-type natriuretic peptide in patients referred to coronary angiography and signs and symptoms of heart failure and preserved ejection fraction.
    Kleber ME; Koller L; Goliasch G; Sulzgruber P; Scharnagl H; Silbernagel G; Grammer TB; Delgado G; Tomaschitz A; Pilz S; März W; Niessner A
    Circ Heart Fail; 2015 Jan; 8(1):25-32. PubMed ID: 25342739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N-terminal pro-B-type natriuretic peptide post-discharge monitoring in the management of patients with heart failure and preserved ejection fraction - a randomized trial: The NICE study.
    Pascual-Figal DA; Hernández-Vicente A; Pastor-Pérez F; Martínez-Sellés M; Solé-González E; Alvarez-García J; García-Pavía P; Varela-Román A; Sánchez PL; Delgado JF; Noguera-Velasco JA; Bayes-Genis A;
    Eur J Heart Fail; 2024 Apr; 26(4):776-784. PubMed ID: 38606524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction.
    Gohar A; Chong JPC; Liew OW; den Ruijter H; de Kleijn DPV; Sim D; Yeo DPS; Ong HY; Jaufeerally F; Leong GKT; Ling LH; Lam CSP; Richards AM
    Eur J Heart Fail; 2017 Dec; 19(12):1638-1647. PubMed ID: 28849609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
    Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
    Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Midregional pro-atrial natriuretic peptide is a superior biomarker to N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure patients with preserved ejection fraction.
    Cui K; Huang W; Fan J; Lei H
    Medicine (Baltimore); 2018 Sep; 97(36):e12277. PubMed ID: 30200170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF.
    Kang SH; Park JJ; Choi DJ; Yoon CH; Oh IY; Kang SM; Yoo BS; Jeon ES; Kim JJ; Cho MC; Chae SC; Ryu KH; Oh BH;
    Heart; 2015 Dec; 101(23):1881-8. PubMed ID: 26319121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal function, N-terminal Pro-B-Type natriuretic peptide, propeptide big-endothelin and patients with heart failure and preserved ejection fraction.
    Gergei I; Krämer BK; Scharnagl H; Stojakovic T; März W
    Peptides; 2019 Jan; 111():112-117. PubMed ID: 29684593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
    Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
    Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Parathyroid hormone is associated with heart failure with preserved ejection fraction.
    Bezgin T; Elveran A; Karagoz A; Canga Y; Dogan C
    Bratisl Lek Listy; 2016; 117(8):442-7. PubMed ID: 27546695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the swedish heart failure register.
    Eriksson B; Wändell P; Dahlström U; Näsman P; Lund LH; Edner M
    Scand J Prim Health Care; 2019 Dec; 37(4):434-443. PubMed ID: 31724475
    [No Abstract]   [Full Text] [Related]  

  • 33. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
    Jhund PS; Anand IS; Komajda M; Claggett BL; McKelvie RS; Zile MR; Carson PE; McMurray JJ
    Eur J Heart Fail; 2015 Aug; 17(8):809-17. PubMed ID: 25921853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prognostic value of N-terminal B-type natriuretic peptide on all-cause mortality in heart failure patients with preserved ejection fraction].
    Cao J; Jin XJ; Zhou J; Chen ZY; Xu DL; Yang XC; Dong W; Li LW; Luo J; Chen L; Fu M; Zhou JM; Ge JB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):875-881. PubMed ID: 31744276
    [No Abstract]   [Full Text] [Related]  

  • 35. Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial).
    Patel RB; Vaduganathan M; Felker GM; Butler J; Redfield MM; Shah SJ
    Am J Cardiol; 2019 May; 123(10):1660-1666. PubMed ID: 30876658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma NT-proBNP levels associated with cardiac structural abnormalities in asymptomatic health examinees with preserved ejection fraction: a retrospective cross-sectional study.
    Nah EH; Kim SY; Cho S; Kim S; Cho HI
    BMJ Open; 2019 Apr; 9(4):e026030. PubMed ID: 31005928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of tPA/PAI-1 complex in patients with heart failure and preserved ejection fraction.
    Winter MP; Kleber ME; Koller L; Sulzgruber P; Scharnagl H; Delgado G; Goliasch G; März W; Niessner A
    Thromb Haemost; 2017 Feb; 117(3):471-478. PubMed ID: 27975104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modified Glasgow Prognostic Score is a novel predictor of clinical outcome in heart failure with preserved ejection fraction.
    Bolat I; Biteker M
    Scand Cardiovasc J; 2020 Jun; 54(3):174-178. PubMed ID: 31965867
    [No Abstract]   [Full Text] [Related]  

  • 39. Characterisation of the patients with suspected heart failure: experience from the SHEAF registry.
    Garg P; Dakshi A; Assadi H; Swift AJ; Naveed U; Fent G; Lewis N; Rogers D; Charalampopoulos A; Al-Mohammad A
    Open Heart; 2021 Jan; 8(1):. PubMed ID: 33431617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
    Kondo T; Campbell R; Jhund PS; Anand IS; Carson PE; Lam CSP; Shah SJ; Vaduganathan M; Zannad F; Zile MR; Solomon SD; McMurray JJV
    JACC Heart Fail; 2024 Aug; 12(8):1442-1455. PubMed ID: 38904646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.